BMS-777607   Click here for help

GtoPdb Ligand ID: 7953

Synonyms: BMS 777607 | BMS777607
PDB Ligand
Compound class: Synthetic organic
Comment: BMS-777607is a selective and orally bioavailable MET tyrosine kinase (hepatocyte growth factor receptor) inhibitor with potential antineoplastic activity. Its discovery is described by Schroeder et al. (2009) [1] where it is compound 10. It also has significant activity against other receptor tyrosine kinases, with details presented in the Biological activity tab..
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 107.95
Molecular weight 512.11
XLogP 5.24
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCOc1ccn(c(=O)c1C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N)c1ccc(cc1)F
Isomeric SMILES CCOc1ccn(c(=O)c1C(=O)Nc1ccc(c(c1)F)Oc1ccnc(c1Cl)N)c1ccc(cc1)F
InChI InChI=1S/C25H19ClF2N4O4/c1-2-35-19-10-12-32(16-6-3-14(27)4-7-16)25(34)21(19)24(33)31-15-5-8-18(17(28)13-15)36-20-9-11-30-23(29)22(20)26/h3-13H,2H2,1H3,(H2,29,30)(H,31,33)
No information available.
Summary of Clinical Use Click here for help
A single Phase 2 clinical trial for advanced or metastatic solid tumors (NCT00605618) has been completed. Development has not progressed beyond Phase 2.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of hepatocyte growth factor (HGF) binding to c-MET disrupts the MET signaling pathway and this may induce cell death in tumour cells driven by c-MET.